Literature DB >> 11747295

Soluble recombinant neprilysin induces aggrecanase-mediated cleavage of aggrecan in cartilage explant cultures.

A Chevrier1, J S Mort, P Crine, C D Hoemann, M D Buschmann.   

Abstract

Neprilysin (neutral endopeptidase, enkephalinase, CALLA, CD10, NEP) is a regulatory Zn metallopeptidase expressed in the brush border membranes of the kidney and has been found in porcine chondrocytes and rat articular cartilage as well as other cell types and tissues. Although its function in cartilage is not currently known, previous observations of high levels of NEP enzymatic activity in the synovial fluid of arthritic patients and on the chondrocyte membranes of human osteoarthritic cartilage have led to the hypothesis that NEP is involved in the inflammation or degradation pathways in articular cartilage. Our study localized endogenous NEP to the membranes of mature bovine articular chondrocytes in a tissue explant model and demonstrated that the addition of soluble recombinant NEP (sNEP) to the culture medium of bovine cartilage explants leads to the degradation of aggrecan through the action of aggrecanase. A 6-day exposure to sNEP was necessary to initiate the degradation, suggesting that the chondrocytes were responding in a delayed manner to an altered composition of regulatory peptides. This NEP-induced degradation was completely inhibited by the NEP inhibitors thiorphan and phosphoramidon. These results suggest that NEP is present as a transmembrane enzyme on articular chondrocytes where it can cleave regulatory peptides and lead to the induction of aggrecanase.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11747295     DOI: 10.1006/abbi.2001.2608

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  1 in total

1.  Neprilysin levels in plasma and synovial fluid of juvenile idiopathic arthritis patients.

Authors:  Gabriele Simonini; Chiara Azzari; Anna Maria Grazia Gelli; Teresa Giani; Giovanni Battista Calabri; Gigliola Leoncini; Angela Del Rosso; Sergio Generini; Rolando Cimaz; Marco Matucci Cerinic; Fernanda Falcini
Journal:  Rheumatol Int       Date:  2004-03-03       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.